(b) the Series C Preferred Share Purchase Agreement dated July 11, 2020 entered into among our Company, Antengene Corporation Co., Ltd. (德琪(浙江)醫藥科技有限公司), Antengene (BVI) Limited, Keith Valley Investment Limited, Antengene Corporation (Hong Kong) Limited (德琪控股有限公司), Antengene Therapeutics Limited, Shanghai Antengene Pharmaceutical Technology Co., Ltd. (上海德琪醫藥科技有限公司), Zhejiang Defu Biopharmaceutical Co., Ltd. (浙江德復生物醫藥科技有限公司), Antengene (AUS) PTY. LTD, Antengene Biotech LLC, Antengene Investment Limited, Zhejiang Antengene Pharmaceuticals Co., Ltd. (浙江德琪製藥有限公司), Antengene (Singapore) Pte. Ltd., Brighton Circle Limited, Sea Quest Limited, Antengene (Shanghai) Pharmaceutical Co., Ltd. (德琪醫藥(上海)有限公司), Dr. Mei, Meiland Pharma Tech Limited, Horsham Angel Investment Limited, Fidelity Investment Trust: Fidelity China Region Fund, Fidelity Investment Trust: Fidelity Emerging Asia Fund, Fidelity Advisor Series VIII: Fidelity Advisor Emerging Asia Fund, Fidelity Investment Trust: Fidelity Series Emerging Markets Opportunities Fund – Health Care Sub, Fidelity Investment Trust: Fidelity Total Emerging Markets Fund – Healthcare Subportfolio, Fidelity Central Investment Portfolios LLC: Fidelity Emerging Markets Equity Central Fund – Health Care Sub, Fidelity Emerging Markets Equity Multi-Asset Base Fund – Health Care, FIAM Emerging Markets Opportunities Commingled Pool – Health Care Sub, Fidelity Emerging Markets Opportunities Institutional Trust – Health Care, Fidelity Investment Trust: Fidelity International Discovery Fund, Fidelity Investment Trust: Fidelity Worldwide Fund – Non-US Equity Sub, Fidelity International Discovery Commingled Pool, Fidelity Investment Trust: Fidelity International Discovery K6 Fund, BlackRock Health Sciences Master Unit Trust, BlackRock Global Funds –World Healthscience Fund, BlackRock Health Sciences Trust II, High Cedar Direct Fund, L.P., City-Scape Pte. Ltd., SUM-II Holdings Limited, CRF Investment Holdings Company Limited, CDG Group Fund L.P., Supercluster Universe Limited, Qiming Venture Partners V, L.P., Qiming Managing Directors Fund V, L.P., Mr. John Francis Chin and Mr. Mark J. Alles in relation to the sale and purchase of Series C-1 Preferred Shares and Series C-2 Preferred Shares for an aggregate consideration of US\$97,382,896;

(c) the second amended and restated shareholders agreement dated July 17, 2020 entered into among our Company, Antengene Corporation Co., Ltd. (德琪(浙江)醫藥科技有限公司), Horsham Angel Investment Limited, Meiland Pharma Tech Limited, Dr. Mei, Horsham Incentive Enterprise Limited, Black Halo Investment Limited, Grand Path Holdings Limited, Celgene China Holdings LLC, Qiming Venture Partners V, L.P., Qiming Managing Directors Fund V, L.P., Golden Sense Ventures Limited, Hongkong Tigermed Co., Limited, Huagai Pharmaceutical Health Industry Venture Capital (Wenzhou) Partnership (Limited Partnership) (華蓋醫藥健康產業創業投資(溫州)合夥企業(有限合夥)), Active Ambience Limited, Begonia Investment Ltd., WuXi PharmaTech Healthcare Fund I L.P., Taikang Kaitai (Cayman) Special Opportunity I, Fidelity Investment Trust: Fidelity China Region Fund, Fidelity Investment Trust: Fidelity Emerging Asia Fund, Fidelity Advisor Series VIII: Fidelity Advisor Emerging Asia Fund, Fidelity Investment Trust: